“I want ordering a phenotype of obesity to be as easy for a doctor as ordering a lipid panel — it’s one tick on the list.”
Andres Acosta, MD, PhD, director of the Mayo Clinic’s Precision Medicine for Obesity laboratory, sees a future where busy primary care physicians will query a patient’s obesity phenotype and receive the information needed to target treatment for this metabolic disorder , just as they do now for type 2 diabetes, hypertension, hyperlipidemia and other chronic conditions.
In this conversation with Patient care®, Acosta discusses plans at Phenomix Sciences, a new Mayo Clinic company backed in part by the American Medical Association’s Health2047 innovation arm, to launch a first-of-its-kind obesity phenotype test and how it will improve obesity treatment to influence.
For more talks with Dr. Acosta:
Andres Acosta, MD, discusses the challenge of heterogeneity in response to obesity treatment
Obesity phenotypes explain what causes the disease and how to target intervention: interview with experts
Building an Obesity Phenotype Step by Step, with Andres Acosta, MD, PhD
Obesity Phenotype-directed treatment choice nearly doubled weight loss in clinical trials: interview with investigator
Andrés Acosta, MD, PhD, is a physician-scientist on the campus of Mayo Clinic in Rochester, Minnesota, specializing in bariatric surgery, upper endoscopy, nutrition and obesity. He is also an assistant professor of medicine at the Mayo Clinic College of Medicine and Science. Acosta’s primary research focus is on the mechanisms and regulation of appetite, satiety and satiety, including the role of gastric function, gastrointestinal hormones, taste preferences, bile acids, and enterohepatic regulation and use of intestinal energy. In addition, studies Dr. Acosta the effect of genetics, pharmacology and endoscopic devices on the regulation of food intake.